TL;DR — Ergothioneine is a sulfur-containing histidine derivative that only fungi and a few bacteria can synthesize — humans get it entirely from diet (mushrooms are by far the richest source) and evolved a dedicated transporter, OCTN1, just to hoard it in mitochondria-dense tissue. A 21-year Swedish cohort of 3,236 adults found higher plasma ergothioneine predicted lower cardiovascular and all-cause mortality, and dietary ergothioneine extended median lifespan 16% in male mice — but the human interventional record is still thin: a metabolic-syndrome RCT has only published its protocol, and a 16-week cognitive trial showed mixed, mostly secondary-endpoint results. Evidence tierTNiC's A/B/C grading of how strong the human research is behind a compound. Full glossary →: C, anchored by real but non-causal cohort data rather than a positive human RCT on a hard endpoint.
Overview & the OCTN1 transporter — why humans hoard a fungal metabolite
Ergothioneine (2-mercaptohistidine trimethylbetaine) is unusual among "antioxidant supplements" in one specific way: no plant or animal can make it. Only certain fungi (mushrooms are the standout dietary source — king oyster, maitake, and porcini run especially high) and a handful of soil bacteria (mycobacteria, actinomycetes) carry the biosynthetic genes. Every animal that uses ergothioneine, including humans, gets it exclusively from diet and imports it through a single high-affinity transporter, OCTN1 (gene SLC22A4, also called the ergothioneine transporter/ETT), which actively concentrates it in tissues that take the heaviest oxidative load — bone marrow, liver, kidney, lens of the eye, erythrocytes, and mitochondria — at levels far above plasma concentration, then retains it there for weeks. That degree of dedicated, cross-species conservation for a compound with no known deficiency syndrome is what led biochemist Bruce Ames to propose it, in a 2018 PNAS framework paper, as a candidate "longevity vitamin" — a micronutrient not essential for immediate survival but plausibly important for long-term tissue maintenance under his triage theory of aging.
Primary hallmarks targeted: Mitochondrial dysfunction · Chronic inflammation · Genomic instability
Smith et al. 2020 (PMID 31672783, Heart 106(9):691–697): in the Malmö Diet and Cancer cohort (n=3,236, no baseline CVD/diabetes), higher plasma ergothioneine was independently associated with lower risk over a 21.4-year median follow-up — hazard ratios per 1-SD increment of 0.85 for coronary disease, 0.79 for cardiovascular mortality, and 0.86 for all-cause mortality. This is real, large, long-follow-up observational data — and it is observational: ergothioneine tracked closely with an independently health-conscious dietary pattern, so the effect could belong partly or wholly to the diet, not the molecule.
Mechanism — a non-autoxidizing thiol, not a typical antioxidant
Most biological thiols (glutathione, cysteine) are unstable: they donate an electron, form a disulfide, and need enzymatic recycling. Ergothioneine is chemically different — at physiological pH it exists almost entirely as the thione tautomer rather than the free thiol, which makes it strongly resistant to autoxidation. It can scavenge hydroxyl radicals, peroxynitrite, and hypochlorous acid and chelate redox-active metals (Cu²⁺, Fe²⁺) without itself becoming a pro-oxidant byproduct — a property that distinguishes it pharmacologically from most supplement-aisle "antioxidants."
| Pathway | Mechanism | Hallmark link |
|---|---|---|
| Direct ROS/RNS scavenging (thione tautomer) | Non-autoxidizing electron donor; quenches •OH, ONOO⁻, HOCl without forming a reactive byproduct | Genomic instability |
| Redox-active metal chelation | Binds Cu²⁺/Fe²⁺, blunting Fenton/Haber-Weiss hydroxyl-radical generation | Genomic instability |
| OCTN1-driven mitochondrial accumulation | Preferentially concentrates in mitochondria of high-turnover, high-oxidative-stress tissue (liver, retina, bone marrow) | Mitochondrial dysfunction |
| Nrf2/NF-κB modulation | Cell and animal studies report antioxidant-gene induction and dampened NF-κB signaling under oxidative challenge (e.g., 7-ketocholesterol-induced endothelial injury models) | Chronic inflammation |
Read the evidence gap honestly
The transporter biology and chemistry are genuinely distinctive — this is not a "me-too" polyphenol antioxidant claim. What's missing is the next step: a completed human RCT showing that raising ergothioneine levels causes the outcomes the cohort study only correlates with. The cognitive and metabolic-syndrome trials designed to answer that question are either still incomplete (protocol-only) or reported mixed, mostly secondary-endpoint results. Treat the mechanism as well-characterized and the clinical case as promising-but-open.
Evidence summary — a strong cohort, a landmark mouse study, and unfinished human RCTs
| Study | Design | N | Duration | Key outcome | Tier |
|---|---|---|---|---|---|
| Smith 2020 (PMID 31672783) | Prospective cohort (Malmö Diet & Cancer) | 3,236 | 21.4 yr median follow-up | ↓CHD, ↓CV mortality, ↓all-cause mortality per SD plasma ERGO | B (observational, non-causal) |
| Katsube 2024 (PMID 38446314, GeroScience) | Lifespan study, male mice, dietary ERGO ~4–5 mg/kg/day | cohort study | Lifetime | +16% median lifespan; +29% 90th-percentile survival age; less age-related fat/weight loss | C (animal) |
| Tian 2021 "ErgMS" (PMID 34715934, Pilot and Feasibility Studies) | RCT protocol, metabolic syndrome, 3-arm (placebo / 5 mg / 30 mg/day) | pilot-scale | 12 wk | Protocol publication only — as of this review, outcome data have not been published | Pending |
| Cheah et al. 2025 (Nutraceuticals 5(3):15; not yet PubMed-indexed) | RCT, older adults with subjective memory complaints, 10 mg vs 25 mg vs placebo | 147 | 16 wk | Plasma ERGO rose 6–16× at 25 mg; some within-group cognitive-domain gains and a 25 mg dose-dependent improvement in prospective memory/sleep-onset, but primary composite memory gain at 25 mg was not sustained between groups | C (preliminary) |
← Swipe for more columns →
Consensus: Tier C. What we know: the transporter biology is genuinely unique, the Malmö cohort is a large, long-follow-up, real association between plasma ergothioneine and hard cardiovascular/mortality outcomes, and dietary ergothioneine extended lifespan in a rigorously conducted male-mouse study. What we don't know: whether raising ergothioneine levels in humans causes any of the cohort's outcomes, since diet quality confounds the association; the completed human RCTs to date are small, short, and have mostly moved secondary or surrogate endpoints rather than a clean primary outcome; and the mouse lifespan result has not yet been replicated or extended to females.
Where ergothioneine disappoints
- The mortality link is association, not proof. The large Malmö cohort ties higher blood ergothioneine to better outcomes — but people with high levels eat more mushrooms and generally eat better; the association may be a marker of a good diet, not an effect of the compound. - Human RCTs are thin. The finished trials are small, short, and mostly move surrogate markers, not a clean primary endpoint — nowhere near the strength of the cohort or the mouse data. - Product content is a lottery. "Mushroom extract" without a stated ERGO amount varies enormously by species and processing; you can pay for very little of the actual compound.
Is ergothioneine worth adding?
Is your primary goal a specific, RCT-confirmed clinical outcome (e.g., cognitive decline, metabolic syndrome)?
The trials designed to test that are incomplete or preliminary — treat ergothioneine as a hypothesis-stage addition, not a proven lever, and prioritize better-evidenced options for that specific goal first
node | Do you want a low-risk, mechanistically distinct antioxidant addition with strong cohort-level (not causal) support?
A trial-anchored 5–25 mg/day is reasonable; increase mushroom intake as a food-first option alongside or instead of supplementing
Defer — the case here is interesting, not urgent
Pregnant, nursing, or considering doses above the EU's approved 30 mg/day adult ceiling — no safety data exists above that range
Educational decision aid — a way to organize the evidence, not a prescription. Doses and timing shown are those used in studies; confirm anything you act on with a clinician or pharmacist.
Dosing protocol
| Parameter | Recommendation | Notes |
|---|---|---|
| Dose | 5–25 mg/day L-ergothioneine | ErgMS pilot used 5 or 30 mg/day; the cognitive RCT used 10 or 25 mg/day and detected dose-dependent secondary effects at 25 mg |
| Regulatory ceiling | Up to 30 mg/day (adults), 20 mg/day (children) | EFSA's 2016/2017 novel-food authorization for synthetic L-ergothioneine set these as the evaluated safe upper limits — not a target dose |
| Food-first option | Mushrooms (king oyster, maitake, porcini) are the richest dietary source by a wide margin | Dietary intake tracks with the cohort's protective association more directly than isolated supplementation does |
| Timing | AM/PM, either is fine | Tissue half-life is measured in weeks — timing within the day has negligible mechanistic rationale |
| Duration before reassessing | 12–16 weeks | Matches the ErgMS and cognitive-RCT windows |
Week-one compliance checklist
- [ ] Confirm the label states synthetic or fermentation-derived L-ergothioneine (not an unstandardized mushroom-extract blend with an unclear ERGO content)
- [ ] Record baseline energy, sleep, and any target symptom before the first dose
- [ ] Note total daily intake including any mushroom-heavy meals if also supplementing
- [ ] Set a 12–16 week review point before judging effect
Monitoring
| Biomarker | Target | Frequency | Action if off-target |
|---|---|---|---|
| Subjective sleep onset / energy | Trending better or stable | Baseline, 12–16 wk | No change → consistent with the trial's largely null primary-endpoint findings; reassess whether this is your priority lever |
| hs-CRP | <1.0 mg/L | Baseline, 12 wk | No movement → mechanistic anti-inflammatory effect has not translated for you specifically |
| Liver enzymes (ALT/AST) | Normal range | Baseline, 12 wk | The cognitive RCT reported a liver-function improvement signal — worth a baseline/follow-up comparison even though it was a secondary finding |
← Swipe for more columns →
Sleep onset / prospective memory (subjective)
No consistent baseline complaint
hs-CRP
Above target
Sleep onset / prospective memory (subjective)
Possible modest improvement, seen mainly at 25 mg in trial data
hs-CRP
Uncertain — no dedicated inflammation-outcome RCT exists yet
Safety, red flags, and contraindications
- Well tolerated in every published trial to date — the ErgMS and cognitive RCTs reported no serious adverse events at 5–30 mg/day.
- Very long tissue retention — because OCTN1 concentrates and holds ergothioneine for weeks, there is little published data on multi-year continuous high-dose use; this is a reason for caution, not a documented harm.
Real unknowns, not just 'talk to your doctor'
- No safety data above the EFSA-evaluated 30 mg/day adult ceiling — do not extrapolate to significantly higher doses based on the mouse lifespan-extension dose, which does not translate directly to a human-equivalent dose.
- Pregnancy and nursing — excluded from the EU novel-food authorization population; no dedicated safety data exists for these groups.
- No established drug-interaction data — ergothioneine has not been systematically screened against common medications; this is an evidence gap, not a cleared-safe claim.
- Unstandardized "mushroom extract" products — ergothioneine content in commercial mushroom extracts varies enormously by species and processing; a product without a stated ERGO content is not equivalent to the synthetic material used in the cited trials.
Synergies and antagonists
| Partner | Rationale | Guide |
|---|---|---|
| Selenium | Selenium is a cofactor for glutathioneYour body's most abundant internal antioxidant, made from glycine, cysteine, and glutamate. Full glossary → peroxidase, the enzymatic antioxidant system that complements ergothioneine's direct, non-enzymatic radical scavenging | Selenium module |
| CoQ10 | Both concentrate in mitochondria-dense tissue; CoQ10 supports the electron-transport chain while ergothioneine buffers mitochondrial oxidative load | CoQ10 module |
| NAC | Shares thiol-pathway biology, though NAC works mainly by replenishing glutathione rather than ergothioneine's non-autoxidizing mechanism — evaluate as complementary, not redundant | NAC module |
SynergyWhen two compounds together produce greater effect than either alone. Full glossary → claims here are mechanistic hypotheses, not tested combinations — no published trial has evaluated ergothioneine stacked with any of these.
What would change this grade. Ergothioneine is C — a striking transporter biology and a real cohort association, but no causal human evidence. A controlled trial showing that raising ergothioneine improves a hard endpoint (not just a surrogate) would move it toward B; the association stays diet-confounded until then.
Who should skip ergothioneine
- Anyone treating the cohort association as proven benefit — it's observational and diet-confounded. - Pregnancy/nursing, or anyone exceeding the EFSA-evaluated 30 mg/day ceiling — no safety data there. - Anyone buying unstandardized "mushroom extract" — without a stated ERGO content it isn't the trial material.
Works against / redundant with
| Antagonist | Conflict | What to do |
|---|---|---|
| A mushroom-rich diet | You may already ingest meaningful ergothioneine from food | Count dietary sources before paying for an isolate |
| — | No characterized drug/supplement antagonists — but that's an evidence gap, not a safety clearance | Treat interactions as unknown, not ruled out |
Personal results template
My Ergothioneine results log
| Date | Week | Dose | Sleep onset (1–10) | hs-CRP | Energy (1–10) | Notes |
|---|---|---|---|---|---|---|
| YYYY-MM-DD | 0 | — | — | — | — | Baseline |
| YYYY-MM-DD | 8 | 5–25 mg | — | — | — | Mid-point |
| YYYY-MM-DD | 16 | 5–25 mg | — | — | — | Primary endpoint, matches cognitive-RCT window |
← Swipe for more columns →
Response criteria (personal, not clinical): - Meaningful: Sleep onset or subjective energy trending better by week 16, consistent with the dose-dependent secondary findings at 25 mg in trial data. - No effect: No change in any tracked marker with confirmed compliance — consistent with the largely null primary-endpoint pattern in the completed trials. - Stop and reassess: Any new or unusual symptom, especially given the limited drug-interaction data available.
See the mitochondrial-support stack
Ergothioneine's mitochondrial concentration overlaps with CoQ10's electron-transport-chain role — see how the two compare on evidence maturity.
CoQ10 moduleReferences
Links open PubMed. TNiC does not sell supplements; citations support education, not medical advice.